Marengo Therapeutics is pioneering a brand-new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer.
Our unique therapeutic platform selectively boosts subsets of a patient’s own T cells, transforming them into potent cancer killers with a unique ability to promote long-term immunity and keep cancer at bay.
An entirely different perspective on tackling cancer, using a novel mode of T cell activation
Marengo scientists have discovered a new way to activate specific T cell subsets and fight tumors by directly targeting Variable β (Vβ) chain variants of the TCR. Our first-in-class bispecific antibody library enables selective activation and expansion of a wide range of different Vβ TCR variants comprising the “germline repertoire”, the entire universe of available T cells awaiting activation to defend the body appropriately when called into action.